Melphalan Hikma

Melphalan, the active ingredient in Melphalan Hikma, is an alkylating agent (nitrogen mustard) presented as an injectable solution for intravenous use. It is employed in the treatment of certain hematologic and solid tumors, including multiple myeloma, ovarian cancer and melanoma, in adult patients and is administered under specialist supervision.

GNH USA supplies Melphalan Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution.

Melphalan is an alkylating chemotherapy agent used in several malignancies that rely on DNA cross‑linking for therapeutic effect. - Multiple myeloma: reduces malignant plasma cell proliferation and improves survival outcomes. - Ovarian cancer: contributes to tumor cell kill as part of combination regimens. - Melanoma: provides cytotoxic activity in advanced disease settings.

Melphalan may cause a range of adverse reactions, varying from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nausea and vomiting: gastrointestinal upset commonly reported. - Myelosuppression: reduced blood cell counts causing anemia, neutropenia or thrombocytopenia. - Fatigue: generalized tiredness affecting daily activities.

Serious or Rare Side Effects: - Secondary malignancies: risk of new cancers such as acute leukemia. - Severe infection: due to profound neutropenia and immune suppression. - Pulmonary toxicity: interstitial pneumonitis or fibrosis.

When using Melphalan, clinicians should observe specific precautions to minimize risks and ensure safe administration. - Baseline blood work: obtain complete blood count and renal function before initiating therapy. - Monitor hematology: perform regular CBCs to detect myelosuppression early. - Hydration: ensure adequate intravenous fluids to reduce renal toxicity. - Concomitant drugs: avoid concurrent use of other myelosuppressive agents unless clinically justified. - Pregnancy and lactation: contraindicated in pregnant or breastfeeding women due to teratogenic potential. - Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Melphalan can interact with other medicines, altering its efficacy or toxicity profile.

Major Interactions (Avoid): - Live vaccines: immunosuppression may increase risk of infection from administered vaccines. - Highly nephrotoxic drugs: concurrent use can exacerbate renal impairment.

Moderate Interactions (Monitor Closely): - Anticoagulants: increased bleeding risk due to thrombocytopenia. - CYP450 inducers: may reduce melphalan plasma levels. - Other alkylating agents: additive myelosuppression. - Granulocyte colony‑stimulating factors: may mask bone marrow recovery.